Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors.

ABSTRACT: Aberrant glycosylation is a hallmark of cancer and is not just a consequence, but also a driver of a malignant phenotype. In prostate cancer, changes in fucosylated and sialylated glycans are common and this has important implications for tumor progression, metastasis, and immune evasion. Glycans hold huge translational potential and new therapies targeting tumor-associated glycans are currently being tested in clinical trials for several tumor types. Inhibitors targeting fucosylation and sialylation have been developed and show promise for cancer treatment, but translational development is hampered by safety issues related to systemic adverse effects. Recently, potent metabolic inhibitors of sialylation and fucosylation were designed that reach higher effective concentrations within the c

SUBMITTER: Orozco-Moreno M 

PROVIDER: S-EPMC10876042 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature